Wisp vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wisp is a telehealth platform for women's sexual and reproductive health providing online consultations and medication delivery for birth control, UTIs, and sexual wellness.
About
Wisp is a women's health telehealth company founded in 2018 that provides convenient online care for sexual and reproductive health conditions including birth control, UTIs, STI treatment, yeast infections, bacterial vaginosis, and sexual wellness. The platform allows patients to consult with licensed providers online and receive prescription medications delivered by mail within 24 to 48 hours without requiring an in-person visit. Wisp operates in all 50 US states and has served over a million patients through its digital-first model. The company raised $25M and targets working women who want convenient access to reproductive health care without taking time off for in-person appointments. Wisp differentiates from general telehealth platforms by specializing exclusively in women's sexual and reproductive health, with clinical protocols and provider training optimized for the conditions most frequently experienced by women. The company offers both one-time treatment consultations and subscription plans for ongoing contraception management. Wisp has built a strong consumer brand through social media and content marketing focused on normalizing conversations about women's sexual health.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.